3
Announcements
Trials
Browse
Landscape
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Thoracic
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Conditions
Breast Neoplasms
2
Urinary Bladder Neoplasms
1
Triple Negative Breast Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Skin Neoplasms
1
Prostatic Neoplasms
1
Neoplasms
1
Melanoma
1
Lung Neoplasms
1
Liver Neoplasms
1
Kidney Neoplasms
1
Head and Neck Neoplasms
1
Endometrial Neoplasms
1
Colorectal Neoplasms
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Hepatocellular
1
Interventions
Sorafenib
22
Bevacizumab
15
pembrolizumab
10
durvalumab
7
Nivolumab
7
Ipilimumab
6
Drug Therapy
6
atezolizumab
5
Talaporfin
5
spartalizumab
4
regorafenib
4
lenvatinib
4
derazantinib
3
Ramucirumab
3
Photochemotherapy
3
Leucovorin
3
Injections
3
Fluorouracil
3
Doxorubicin
3
tremelimumab
2
toripalimab
2
seocalcitol
2
relatlimab
2
phosphomannopentaose sulfate
2
liposomal doxorubicin
2
exatecan
2
cabozantinib
2
brivanib
2
Phototherapy
2
Oxaliplatin
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Liver Neoplasms
×
Biopsy, Large-Core Needle
×
Clear all
NCT05520099
2026-04-29
ELEPHAS-02
Elephas
Active not recruiting
416 enrolled